Surgical route and pathological risk factors in early cervical cancer - Node Zero (SURPEC-N0)

T S Shylasree(Homi Bhabha National Institute), Rajendra Kerkar(Homi Bhabha National Institute), Lavanya Gurram(Homi Bhabha National Institute), Palak Popat(Tata Memorial Hospital), Amita Maheshwari(Homi Bhabha National Institute), Supriya Chopra(Tata Memorial Hospital), Santosh Menon(Homi Bhabha National Institute), Akshay Patil(Hanyang University), Stuti Gupta(Homi Bhabha National Institute), Pooja Singh(National Institute of Technology Tiruchirappalli), Umesh Mahantshetty(Homi Bhabha National Institute)
Journal of Cancer Metastasis and Treatment
January 1, 2022
10.20517/2394-4722.2022.10
Cited by 0

Related Papers

The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
|Clinical and Translational Radiation Oncology|2018|932
Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study
|Radiotherapy and Oncology|2016|695
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
|The Lancet Oncology|2021|624
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
|Journal of Clinical Oncology|2021|338
Dose–volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study
|Radiotherapy and Oncology|2016|268